Compare UIS & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UIS | NGEN |
|---|---|---|
| Founded | 1942 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.5M | 200.0M |
| IPO Year | 1994 | 2018 |
| Metric | UIS | NGEN |
|---|---|---|
| Price | $2.59 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.67 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 571.2K | 552.4K |
| Earning Date | 05-05-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,950,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $1.58 |
| 52 Week High | $4.98 | $5.93 |
| Indicator | UIS | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 71.43 |
| Support Level | $2.58 | $1.62 |
| Resistance Level | $2.65 | $4.44 |
| Average True Range (ATR) | 0.11 | 0.14 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 17.54 | 88.96 |
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.